Format

Send to

Choose Destination
Semin Immunopathol. 2016 Jan;38(1):11-27. doi: 10.1007/s00281-015-0539-8. Epub 2015 Nov 16.

Update on psoriasis immunopathogenesis and targeted immunotherapy.

Author information

1
St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London, London, UK.
2
Department of Medical and Molecular Genetics, Division of Genetics and Molecular Medicine, King's College London, London, UK.
3
St John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London, London, UK. jonathan.barker@kcl.ac.uk.

Abstract

Over recent years, significant progress has been made in characterisation of the underlying pathogenic mechanisms in psoriasis, a common cutaneous disease that is associated with major systemic co-morbidity and reduced life expectancy. Basic science discoveries have informed the design of novel therapeutic approaches, many of which are now under evaluation in late-stage clinical trials. Here we describe the complex interplay between immune cell types and cytokine networks that acts within self-perpetuating feedback loops to drive cutaneous inflammation in psoriasis. Genetic studies have been pivotal in the construction of the disease model and more recently have uncovered a distinct aetiology for rare, pustular variants of psoriasis. The translation of mechanistic insights into potential advancements in clinical care will also be described, including several treatments that target the interleukin-23 (IL-23)/T17 immune axis.

PMID:
26573299
PMCID:
PMC4706579
DOI:
10.1007/s00281-015-0539-8
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center